MAP kinase-interacting kinases - Emerging targets against cancer

Chemistry and Biology

Volumn 21, Issue 4, 2014, Pages 441-452

  Diab, Sarah ^a   Kumarasiri, Malika ^a   Yu, Mingfeng ^a   Teo, Theodosia ^a   Proud, Christopher ^b   Milne, Robert ^a   Wang, Shudong ^a  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; INITIATION FACTOR 4E; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INTERACTING KINASE; PHOSPHOTRANSFERASE INHIBITOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MOLECULAR LIBRARY; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE;

ANTINEOPLASTIC ACTIVITY; CANCER GROWTH; ENZYME ACTIVATION; ENZYME CONFORMATION; ENZYME INHIBITION; HUMAN; MALIGNANT TRANSFORMATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; REVIEW; TRANSLATION INITIATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; ENZYMOLOGY; METABOLISM; MOLECULAR LIBRARY; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PHARMACOLOGY; PHOSPHORYLATION; STRUCTURE ACTIVITY RELATION;

EUKARYOTA;

ANIMALS; ANTINEOPLASTIC AGENTS; EUKARYOTIC INITIATION FACTOR-4E; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; SMALL MOLECULE LIBRARIES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84899624581     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2014.01.011     Document Type: Review

References (65)

1. L. Adesso, S. Calabretta, F. Barbagallo, G. Capurso, E. Pilozzi, R. Geremia, G. Delle Fave, and C. Sette Gemcitabine triggers a pro-survival response in pancreatic cancer cells through activation of the MNK2/eIF4E pathway Oncogene 32 2013 2848 2857
2. J.K. Altman, A. Szilard, B.W. Konicek, P.W. Iversen, B. Kroczynska, H. Glaser, A. Sassano, E. Vakana, J.R. Graff, and L.C. Platanias Inhibition of Mnk kinase activity by cercosporamide and suppressive effects on acute myeloid leukemia precursors Blood 121 2013 3675 3681
3. S. Assouline, B. Culjkovic, E. Cocolakis, C. Rousseau, N. Beslu, A. Amri, S. Caplan, B. Leber, D.-C. Roy, W.H. Miller Jr., and K.L. Borden Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin Blood 114 2009 257 260
4. J. Bain, L. Plater, M. Elliott, N. Shpiro, C.J. Hastie, H. McLauchlan, I. Klevernic, J.S.C. Arthur, D.R. Alessi, and P. Cohen The selectivity of protein kinase inhibitors: a further update Biochem. J. 408 2007 297 315
5. L. Beretta, A.C. Gingras, Y.V. Svitkin, M.N. Hall, and N. Sonenberg Rapamycin blocks the phosphorylation of 4E-BP1 and inhibits cap-dependent initiation of translation EMBO J. 15 1996 658 664
6. A. Bianchini, M. Loiarro, P. Bielli, R. Busà, M.P. Paronetto, F. Loreni, R. Geremia, and C. Sette Phosphorylation of eIF4E by MNKs supports protein synthesis, cell cycle progression and proliferation in prostate cancer cells Carcinogenesis 29 2008 2279 2288
7. K.L.B. Borden Targeting the oncogene eIF4E in cancer: from the bench to clinical trials Clin. Invest. Med. 34 2011 E315 E319
8. M. Buxadé, J.L. Parra, S. Rousseau, N. Shpiro, R. Marquez, N. Morrice, J. Bain, E. Espel, and C.G. Proud The Mnks are novel components in the control of TNF α biosynthesis and phosphorylate and regulate hnRNP A1 Immunity 23 2005 177 189
9. M. Buxade, J.L. Parra-Palau, and C.G. Proud The Mnks: MAP kinase-interacting kinases (MAP kinase signal-integrating kinases) Front. Biosci. 13 2008 5359 5373
10. M.S. Cohen, C. Zhang, K.M. Shokat, and J. Taunton Structural bioinformatics-based design of selective, irreversible kinase inhibitors Science 308 2005 1318 1321
11. B. Culjkovic, I. Topisirovic, and K.L.B. Borden Controlling gene expression through RNA regulons: the role of the eukaryotic translation initiation factor eIF4E Cell Cycle 6 2007 65 69
12. A. De Benedetti, and J.R. Graff eIF-4E expression and its role in malignancies and metastases Oncogene 23 2004 3189 3199
13. N. Eswar, B. Webb, M.A. Marti-Renom, M. Madhusudhan, D. Eramian, M.Y. Shen, U. Pieper, and A. Sali Comparative protein structure modeling using Modeller Curr. Protoc. Bioinformatics 5 2006 5.6
14. S. Fan, S.S. Ramalingam, J. Kauh, Z. Xu, F.R. Khuri, and S.Y. Sun Phosphorylated eukaryotic translation initiation factor 4 (eIF4E) is elevated in human cancer tissues Cancer Biol. Ther. 8 2009 1463 1469
15. K. Feoktistova, E. Tuvshintogs, A. Do, and C.S. Fraser Human eIF4E promotes mRNA restructuring by stimulating eIF4A helicase activity Proc. Natl. Acad. Sci. USA 110 2013 13339 13344
16. L. Furic, L. Rong, O. Larsson, I.H. Koumakpayi, K. Yoshida, A. Brueschke, E. Petroulakis, N. Robichaud, M. Pollak, and L.A. Gaboury et al. eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression Proc. Natl. Acad. Sci. USA 107 2010 14134 14139
17. J.R. Graff, B.W. Konicek, T.M. Vincent, R.L. Lynch, D. Monteith, S.N. Weir, P. Schwier, A. Capen, R.L. Goode, and M.S. Dowless et al. Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity J. Clin. Invest. 117 2007 2638 2648
18. D.S. Hong, R. Kurzrock, Y. Oh, J. Wheler, A. Naing, L. Brail, S. Callies, V. André, S.K. Kadam, and A. Nasir et al. A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer Clin. Cancer Res. 17 2011 6582 6591
19. J. Hou, F. Lam, C. Proud, and S. Wang Targeting Mnks for cancer therapy Oncotarget 3 2012 118 131
20. J. Hou, T. Teo, M.J. Sykes, and S. Wang Insights into the importance of DFD-motif and insertion I1 in stabilizing the DFD-out conformation of Mnk2 kinase ACS Med. Chem. Lett. 4 2013 736 741
21. R. Jauch, S. Jäkel, C. Netter, K. Schreiter, B. Aicher, H. Jäckle, and M.C. Wahl Crystal structures of the Mnk2 kinase domain reveal an inhibitory conformation and a zinc binding site Structure 13 2005 1559 1568
22. R. Jauch, M.K. Cho, S. Jäkel, C. Netter, K. Schreiter, B. Aicher, M. Zweckstetter, H. Jäckle, and M.C. Wahl Mitogen-activated protein kinases interacting kinases are autoinhibited by a reprogrammed activation segment EMBO J. 25 2006 4020 4032
23. M.W. Karaman, S. Herrgard, D.K. Treiber, P. Gallant, C.E. Atteridge, B.T. Campbell, K.W. Chan, P. Ciceri, M.I. Davis, and P.T. Edeen et al. A quantitative analysis of kinase inhibitor selectivity Nat. Biotechnol. 26 2008 127 132
24. A. Kentsis, I. Topisirovic, B. Culjkovic, L. Shao, and K.L. Borden Ribavirin suppresses eIF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap Proc. Natl. Acad. Sci. USA 101 2004 18105 18110
25. U. Knauf, C. Tschopp, and H. Gram Negative regulation of protein translation by mitogen-activated protein kinase-interacting kinases 1 and 2 Mol. Cell. Biol. 21 2001 5500 5511
26. B.W. Konicek, J.R. Stephens, A.M. McNulty, N. Robichaud, R.B. Peery, C.A. Dumstorf, M.S. Dowless, P.W. Iversen, S. Parsons, and K.E. Ellis et al. Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastases Cancer Res. 71 2011 1849 1857
27. A.P. Kornev, and S.S. Taylor Defining the conserved internal architecture of a protein kinase Biochim. Biophys. Acta 1804 2010 440 444
28. A.P. Kornev, N.M. Haste, S.S. Taylor, and L.F. Eyck Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism Proc. Natl. Acad. Sci. USA 103 2006 17783 17788
29. I. Kufareva, and R. Abagyan Type-II kinase inhibitor docking, screening, and profiling using modified structures of active kinase states J. Med. Chem. 51 2008 7921 7932
30. S. Li, J. Fu, and M. Suzanne Lentzsch Cap-dependent protein translation initiation in multiple myeloma: an attractive target for therapy S. Lentzsch, Genetic and Molecular Epidemiology of Multiple Myeloma 2013 Springer New York 43 57
31. S. Liang, R. Guo, Z. Zhang, D. Liu, H. Xu, Z. Xu, X. Wang, and L. Yang Upregulation of the eIF4E signaling pathway contributes to the progression of gastric cancer, and targeting eIF4E by perifosine inhibits cell growth Oncol. Rep. 29 2013 2422 2430
32. S. Lim, T.Y. Saw, M. Zhang, M.R. Janes, K. Nacro, J. Hill, A.Q. Lim, C.-T. Chang, D.A. Fruman, and D.A. Rizzieri et al. Targeting of the MNK-eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell function Proc. Natl. Acad. Sci. USA 110 2013 E2298 E2307
33. Y. Liu, and N.S. Gray Rational design of inhibitors that bind to inactive kinase conformations Nat. Chem. Biol. 2 2006 358 364
34. Q. Liu, Y. Sabnis, Z. Zhao, T. Zhang, S.J. Buhrlage, L.H. Jones, and N.S. Gray Developing irreversible inhibitors of the protein kinase cysteinome Chem. Biol. 20 2013 146 159
35. Y. Mamane, E. Petroulakis, L. Rong, K. Yoshida, L.W. Ler, and N. Sonenberg eIF4E - from translation to transformation Oncogene 23 2004 3172 3179
36. Y. Mamane, E. Petroulakis, Y. Martineau, T.-A. Sato, O. Larsson, V.K. Rajasekhar, and N. Sonenberg Epigenetic activation of a subset of mRNAs by eIF4E explains its effects on cell proliferation PLoS ONE 2 2007 e242
37. V. Martinez-Marignac, M. Shawi, E. Pinedo-Carpio, X. Wang, L. Panasci, W. Miller, F. Pettersson, and R. Aloyz Pharmacological targeting of eIF4E in primary CLL lymphocytes Blood Cancer J. 3 2013 e146
38. M. Marzec, X. Liu, M. Wysocka, A.H. Rook, N. Odum, and M.A. Wasik Simultaneous inhibition of mTOR-containing complex 1 (mTORC1) and MNK induces apoptosis of cutaneous T-cell lymphoma (CTCL) cells PLoS ONE 6 2011 e24849
39. Z. Nasr, F. Robert, J.A. Porco Jr., W.J. Muller, and J. Pelletier eIF4F suppression in breast cancer affects maintenance and progression Oncogene 32 2013 861 871
40. A. O'Loghlen, V.M. González, D. Piñeiro, M.I. Pérez-Morgado, M. Salinas, and M.E. Martín Identification and molecular characterization of Mnk1b, a splice variant of human MAP kinase-interacting kinase Mnk1 Exp. Cell Res. 299 2004 343 355
41. N. Oridate, H.-J. Kim, X. Xu, and R. Lotan Growth inhibition of head and neck squamous carcinoma cells by small interfering RNAs targeting eIF4E or cyclin D1 alone or combined with cisplatin Cancer Biol. Ther. 4 2005 318 323
42. J. Oyarzabal, N. Zarich, M.I. Albarran, I. Palacios, M. Urbano-Cuadrado, G. Mateos, I. Reymundo, O. Rabal, A. Salgado, and A. Corrionero et al. Discovery of mitogen-activated protein kinase-interacting kinase 1 inhibitors by a comprehensive fragment-oriented virtual screening approach J. Med. Chem. 53 2010 6618 6628
43. J.L. Parra, M. Buxadé, and C.G. Proud Features of the catalytic domains and C termini of the MAPK signal-integrating kinases Mnk1 and Mnk2 determine their differing activities and regulatory properties J. Biol. Chem. 280 2005 37623 37633
44. A. Pause, G.J. Belsham, A.-C. Gingras, O. Donzé, T.-A. Lin, J.C. Lawrence Jr., and N. Sonenberg Insulin-dependent stimulation of protein synthesis by phosphorylation of a regulator of 5′-cap function Nature 371 1994 762 767
45. S. Pyronnet, H. Imataka, A.C. Gingras, R. Fukunaga, T. Hunter, and N. Sonenberg Human eukaryotic translation initiation factor 4G (eIF4G) recruits mnk1 to phosphorylate eIF4E EMBO J. 18 1999 270 279
46. R.E. Rhoads Cap recognition and the entry of mRNA into the protein synthesis initiation cycle Trends Biochem. Sci. 13 1988 52 56
47. I.M. Serafimova, M.A. Pufall, S. Krishnan, K. Duda, M.S. Cohen, R.L. Maglathlin, J.M. McFarland, R.M. Miller, M. Frödin, and J. Taunton Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles Nat. Chem. Biol. 8 2012 471 476
48. W. Sherman, T. Day, M.P. Jacobson, R.A. Friesner, and R. Farid Novel procedure for modeling ligand/receptor induced fit effects J. Med. Chem. 49 2006 534 553
49. M. Shveygert, C. Kaiser, S.S. Bradrick, and M. Gromeier Regulation of eukaryotic initiation factor 4E (eIF4E) phosphorylation by mitogen-activated protein kinase occurs through modulation of Mnk1-eIF4G interaction Mol. Cell. Biol. 30 2010 5160 5167
50. R.L.A. Silva, and H.G. Wendel MNK, EIF4E and targeting translation for therapy Cell Cycle 7 2008 553 555
51. J. Singh, R.C. Petter, T.A. Baillie, and A. Whitty The resurgence of covalent drugs Nat. Rev. Drug Discov. 10 2011 307 317
52. K. Slentz-Kesler, J.T. Moore, M. Lombard, J. Zhang, R. Hollingsworth, and M.P. Weiner Identification of the human Mnk2 gene (MKNK2) through protein interaction with estrogen receptor β Genomics 69 2000 63 71
53. S.S. Taylor, and A.P. Kornev Protein kinases: evolution of dynamic regulatory proteins Trends Biochem. Sci. 36 2011 65 77
54. T. Ueda, R. Watanabe-Fukunaga, H. Fukuyama, S. Nagata, and R. Fukunaga Mnk2 and Mnk1 are essential for constitutive and inducible phosphorylation of eukaryotic initiation factor 4E but not for cell growth or development Mol. Cell. Biol. 24 2004 6539 6549
55. T. Ueda, M. Sasaki, A.J. Elia, I.I.C. Chio, K. Hamada, R. Fukunaga, and T.W. Mak Combined deficiency for MAP kinase-interacting kinase 1 and 2 (Mnk1 and Mnk2) delays tumor development Proc. Natl. Acad. Sci. USA 107 2010 13984 13990
56. A.J. Waskiewicz, A. Flynn, C.G. Proud, and J.A. Cooper Mitogen-activated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2 EMBO J. 16 1997 1909 1920
57. H.G. Wendel, R.L.A. Silva, A. Malina, J.R. Mills, H. Zhu, T. Ueda, R. Watanabe-Fukunaga, R. Fukunaga, J. Teruya-Feldstein, J. Pelletier, and S.W. Lowe Dissecting eIF4E action in tumorigenesis Genes Dev. 21 2007 3232 3237
58. M.J. Wheater, P.W.M. Johnson, and J.P. Blaydes The role of MNK proteins and eIF4E phosphorylation in breast cancer cell proliferation and survival Cancer Biol. Ther. 10 2010 728 735
59. M. Wu, Y. Liu, X. Di, H. Kang, H. Zeng, Y. Zhao, K. Cai, T. Pang, S. Wang, Y. Yao, and X. Hu EIF4E over-expresses and enhances cell proliferation and cell cycle progression in nasopharyngeal carcinoma Med. Oncol. 30 2013 400
60. J. Xu, A. Chen, J. Joy, V.J. Xavier, E.H. Ong, J. Hill, and C.L. Chai Rational design of resorcylic acid lactone analogues as covalent MNK1/2 kinase inhibitors by tuning the reactivity of an enamide Michael acceptor ChemMedChem 8 2013 1483 1494
61. P. Yellen, A. Chatterjee, A. Preda, and D.A. Foster Inhibition of S6 kinase suppresses the apoptotic effect of eIF4E ablation by inducing TGF-β-dependent G1 cell cycle arrest Cancer Lett. 333 2013 239 243
62. M. Zhang, W. Fu, S. Prabhu, J.C. Moore, J. Ko, J.W. Kim, B.J. Druker, V. Trapp, J. Fruehauf, and H. Gram et al. Inhibition of polysome assembly enhances imatinib activity against chronic myelogenous leukemia and overcomes imatinib resistance Mol. Cell. Biol. 28 2008 6496 6509
63. J. Zhang, P.L. Yang, and N.S. Gray Targeting cancer with small molecule kinase inhibitors Nat. Rev. Cancer 9 2009 28 39
64. F.F. Zhou, M. Yan, G.F. Guo, F. Wang, H.J. Qiu, F.M. Zheng, Y. Zhang, Q. Liu, X.F. Zhu, and L.P. Xia Knockdown of eIF4E suppresses cell growth and migration, enhances chemosensitivity and correlates with increase in Bax/Bcl-2 ratio in triple-negative breast cancer cells Med. Oncol. 28 2011 1302 1307
65. F. Zuccotto, E. Ardini, E. Casale, and M. Angiolini Through the "gatekeeper door": exploiting the active kinase conformation J. Med. Chem. 53 2010 2681 2694